A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Expanded Access
Expanded Access
Available
- Available: Expanded access is currently available for this investigational treatment, and patients who are not participants in the clinical study may be able to gain access to the drug, biologic, or medical device being studied.
- No longer available: Expanded access was available for this intervention previously but is not currently available and will not be available in the future.
- Temporarily not available: Expanded access is not currently available for this intervention but is expected to be available in the future.
- Approved for marketing: The intervention has been approved by the U.S. Food and Drug Administration for use by the public.
Contacts and Locations
Study Locations
-
-
New South Wales
-
Chatswood, New South Wales, Australia
-
-
South Australia
-
Adelaide, South Australia, Australia
-
-
Victoria
-
Clayton, Victoria, Australia
-
Fitzroy, Victoria, Australia
-
Parkville, Victoria, Australia
-
West Heidelberg, Victoria, Australia
-
-
-
-
-
Gent, Belgium
-
Kortrijk, Belgium
-
-
-
-
Alberta
-
Calgary, Alberta, Canada
-
Edmonton, Alberta, Canada
-
-
Ontario
-
Toronto, Ontario, Canada
-
Windsor, Ontario, Canada
-
-
Saskatchewan
-
Sakaskatoon, Saskatchewan, Canada
-
-
-
-
-
Brno, Czechia
-
Litomysl, Czechia
-
Ostava, Czechia
-
Ostrava-Trebovice, Czechia
-
Praha 2, Czechia
-
Praha-4, Czechia
-
-
-
-
-
Aschaffenburg, Germany
-
Halle (Saale), Germany
-
Mainz, Germany
-
Regensburg, Germany
-
-
-
-
-
Goteborg, Sweden
-
Lund, Sweden
-
Stockholm, Sweden
-
Uppsala, Sweden
-
-
-
-
Arizona
-
Phoenix, Arizona, United States
-
-
California
-
Fresno, California, United States
-
Pasadena, California, United States
-
-
Colorado
-
Denver, Colorado, United States
-
-
Florida
-
Miami, Florida, United States
-
Orlando, Florida, United States
-
-
Georgia
-
Conyers, Georgia, United States
-
Macon, Georgia, United States
-
-
Illinois
-
Peoria, Illinois, United States
-
-
Kentucky
-
Lexington, Kentucky, United States
-
-
Massachusetts
-
Burlington, Massachusetts, United States
-
-
Nevada
-
Las Vegas, Nevada, United States
-
-
New Jersey
-
Summit, New Jersey, United States
-
-
New York
-
Bronx, New York, United States
-
Mineola, New York, United States
-
New York, New York, United States
-
-
North Carolina
-
Hickory, North Carolina, United States
-
-
Ohio
-
Kettering, Ohio, United States
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
-
-
Tennessee
-
Germantown, Tennessee, United States
-
-
Texas
-
Austin, Texas, United States
-
Dallas, Texas, United States
-
Houston, Texas, United States
-
-
Virginia
-
Danville, Virginia, United States
-
-
West Virginia
-
Charleston, West Virginia, United States
-
-
Wisconsin
-
Waukesha, Wisconsin, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects from 16 to 75 years, both inclusive
- Well-characterized focal epilepsy or epileptic syndrome
- Subjects having at least 2 but not exceeding 40 partial onset seizures, whether or not secondarily generalized per 4 weeks during the 8-week Baseline Period
- Subjects on a stable dose of at least 1 but no more than 2 concomitant Antiepileptic Drugs (AEDs) with the second AED ≤ 50 % of the minimum recommended maintenance dose
Exclusion Criteria:
- Seizure type IA non-motor as only seizure type
- History or presence of seizures occurring too frequently or indistinctly separated to be reliably counted during the 6 months preceding Visit 1 or during Baseline
- Other serious uncontrolled disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Brivaracetam 50 mg
50 mg/day
|
25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg > 20 mg) for subjects not participating in the follow-up study)
Other Names:
25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg > 50 mg > 20 mg) for subjects not participating in the follow-up study)
Other Names:
|
|
Experimental: Brivaracetam 100 mg
100 mg/day
|
25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg > 20 mg) for subjects not participating in the follow-up study)
Other Names:
25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg > 50 mg > 20 mg) for subjects not participating in the follow-up study)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Cumulative Exit Rate at 112 Days After the Beginning of the Baseline Antiepileptic Drug (AED) Tapering Phase
Time Frame: From Week 1 up to Week 17
|
The cumulative exit rate was estimated using Kaplan-Meier methods and was based on the duration between start of the Evaluation Period (EP) and the earliest date the first exit criterion was met for each subject.
Subjects completing the EP without meeting an exit criterion were censored on Day 112.
The primary comparison was BRV 50 mg/day vs a historical control.
The upper limit of the 2-sided 95 % Confidence Interval for the estimate was compared to the historical lower bound estimate of 0.722.
|
From Week 1 up to Week 17
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The Number of Patients Reporting at Least One Treatment-Emergent Adverse Event (TEAE) During the Course of the Study
Time Frame: Baseline through Re-conversion (approximately 31 weeks)
|
Baseline through Re-conversion (approximately 31 weeks)
|
|
The Number of Patient Withdrawal Due to Adverse Events (AEs) During the Course of the Study
Time Frame: Baseline through Re-conversion (approximately 31 weeks)
|
Baseline through Re-conversion (approximately 31 weeks)
|
|
The Number of Patients Reporting at Least One Serious Adverse Event (SAE) During the Course of the Study
Time Frame: Baseline through Re-conversion (approximately 31 weeks)
|
Baseline through Re-conversion (approximately 31 weeks)
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- N01276
- 2008-000144-14 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.